SCHEMBL3321100

SCHEMBL3321100

CN(Cc1ccc(Cl)s1)C(=O)CC12CC3CC(CC(C3)C1)C2

nearest known ligand 0.65

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 8/20 0.65
CYP3A4 P08684 2/20 0.65
KMT2A Q03164 2/20 0.59
ALDH1A1 P00352 2/20 0.59
HTT P42858 1/20 0.59
RAB9A P51151 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
MEN1 O00255 1/20 0.50
NPC1 O15118 1/20 0.50
P2RX7 Q99572 5/20 0.44
GAA P10253 1/20 0.43
EPHX2 P34913 1/20 0.42
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3321009 0.86 HSD11B1 (0.66) HSD11B1CYP3A4KMT2AALDH1A1HTT
SCHEMBL3319565 0.86 HSD11B1 (0.66) HSD11B1CYP3A4KMT2AALDH1A1HTT
SCHEMBL3321426 0.83 HSD11B1 (0.62) HSD11B1CYP3A4KMT2AALDH1A1HTT
SCHEMBL3322535 0.82 HSD11B1 (0.63) HSD11B1CYP3A4KMT2AALDH1A1HTT
SCHEMBL3327910 0.79 HSD11B1 (1.00) HSD11B1CYP3A4KMT2AALDH1A1RAB9A
SCHEMBL3323115 0.78 HSD11B1 (0.65) HSD11B1CYP3A4KMT2AALDH1A1HTT
SCHEMBL3318181 0.76 HSD11B1 (0.66) HSD11B1CYP3A4KMT2AALDH1A1MEN1
SCHEMBL3322470 0.74 HSD11B1 (0.67) HSD11B1CYP3A4KMT2AALDH1A1MEN1
SCHEMBL3324146 0.73 HSD11B1 (1.00) HSD11B1CYP3A4KMT2AALDH1A1RAB9A
SCHEMBL3321905 0.72 HSD11B1 (0.70) HSD11B1CYP3A4KMT2AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100120789-A1 Compound STERIX LIMITED (GB) 2010-05-13 US disclosed
US-20100120789-A1 Compound STERIX LIMITED (GB) 2010-05-13 US disclosed
US-20100120789-A1 Compound STERIX LIMITED (GB) 2010-05-13 US disclosed
US-20090042929-A1 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors STERIX LIMITED (GB) 2009-02-12 US disclosed
US-20090042929-A1 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors STERIX LIMITED (GB) 2009-02-12 US disclosed
US-20090042929-A1 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors STERIX LIMITED (GB) 2009-02-12 US disclosed
EP-1861384-A1 11-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS Sterix Limited (GB) 2007-12-05 EP disclosed
WO-2006100502-A1 11-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS STERIX LIMITED (GB) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042929-A1 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors HSD3B1, HSD3B2, HSD11B1 HSD11B1 3/4885CYP3A4 72/4885KMT2A 3083/4885
US-20100120789-A1 Compound NR0B2, NR0B1, NR4A1 HSD11B1 73/4885CYP3A4 100/4885KMT2A 2533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.